Genentech expects two advisory committee reviews
Executive Summary
Genentech is hoping for third quarter FDA advisory committee review of Raptiva (efalizumab) for moderate to severe plaque psoriasis in patients 18 and older, firm says during investor meeting March 14. BLA for the recombinant humanized monoclonal antibody was filed by Genentech and XOMA in December. Firm also expects Pulmonary-Allergy Drugs Advisory Committee review of Xolair (omalizumab) for moderate to severe allergic asthma in patients 12 and older ahead of an expected action date on the application by mid-year...